Literature DB >> 9159617

Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria.

F H Ellis1, G J Heatley, M J Krasna, W A Williamson, K Balogh.   

Abstract

OBJECTIVE: A review of findings and results after standard resection for carcinoma of the esophagus and cardia without neoadjuvant therapy was done to provide a basis for comparison with current reports of radical resection and neoadjuvant therapy.
METHODS: A 24-year experience on one surgical service with 454 operations for carcinoma of the esophagus and cardia was reviewed. A comparison of findings and results in three consecutive 8-year intervals was analyzed, and new staging criteria were developed and compared with those currently favored by the American Joint Committee on Cancer.
RESULTS: From January 1, 1970, to January 1, 1994, 454 patients with carcinoma of the esophagus or cardia underwent operation, of whom 408 (90%) had esophagogastrectomy with a 30-day mortality rate of 2.5% and an additional hospital mortality rate of 1.2%. Of the 121 complications (30.7%), 71 (18%) were major and 50 (12.7%) were minor. Cardiovascular complications predominated. The overall 5-year survival was 24.7%, with a 33.7% survival after complete resections in the most recent interval under study. Palliation of dysphagia was achieved in nearly 80% of patients who survived the operation. During the three intervals under review, resectability, mortality, and complication rates remained constant. The percentages of left thoracotomies and transhiatal resections increased, and there was a decrease in thoracoabdominal incisions. The percentages of patients with Barrett's esophagus and stage 0 and I tumors increased. The percentage of complete resections (R0) increased, whereas that for resections with residual microscopic tumor (R1) decreased, and there was no change in the percentage of patients with residual gross tumor after resection (R2). Modified WNM staging criteria are proposed that provide better prognostic stratification of the disease than those currently favored by The American Joint Committee on Cancer.
CONCLUSIONS: Standard esophagogastrectomy is applicable in 90% of patients with operable carcinoma of the esophagus or cardia, with consistently low mortality and morbidity rates and satisfactory palliation of dysphagia. The 5-year survival (24.7% overall) remains suboptimal, but the current figure for complete resections (33.7%) is encouraging. There is a need for revision of the current American Joint Committee on Cancer staging criteria.

Entities:  

Mesh:

Year:  1997        PMID: 9159617     DOI: 10.1016/S0022-5223(97)70256-3

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  30 in total

1.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

2.  The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer.

Authors:  Simon Law; Dora L W Kwong; Kam-Ho Wong; Ka-Fai Kwok; John Wong
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

Review 3.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

4.  Adenocarcinoma of the stomach: a review.

Authors:  James M McLoughlin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

Review 5.  Surgical treatment of superficial esophageal cancer.

Authors:  Mitsuo Tachibana; Shoichi Kinugasa; Muneaki Shibakita; Yasuhito Tonomoto; Shinji Hattori; Ryoji Hyakudomi; Hiroshi Yoshimura; Dipok Kumar Dhar; Naofumi Nagasue
Journal:  Langenbecks Arch Surg       Date:  2006-07-08       Impact factor: 3.445

6.  Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.

Authors:  Dan Comay; Gord Blackhouse; Ron Goeree; David Armstrong; John K Marshall
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

7.  A novel approach to cancer staging: application to esophageal cancer.

Authors:  Hemant Ishwaran; Eugene H Blackstone; Carolyn Apperson-Hansen; Thomas W Rice
Journal:  Biostatistics       Date:  2009-06-05       Impact factor: 5.899

8.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 9.  Surgical management of esophageal malignancy.

Authors:  Dennis Blom
Journal:  Curr Gastroenterol Rep       Date:  2003-06

10.  Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus.

Authors:  Nasser Altorki; Michael Kent; Cathy Ferrara; Jeffrey Port
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.